this post was submitted on 02 Jan 2024
945 points (98.6% liked)
Technology
59374 readers
3671 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
Also sounds very hard to do a proper controlled trial on. Every treatment produces a different protein, so there's no consistent factor to test except for the delivery mechanism.
There's still ways but not trivial. You have to do multifactor analysis, but it's gonna have a ton of noise unless you have a large sample of different people with recurring "neoantigens". It's similar to how drug side effects are tracked for people who take multiple medicines, you compare against populations which share different combinations of the same factors.
Multifactor analysis still requires an underlying commonality. People taking multiple drugs are all still taking the drug being trialed. You're removing the confounding factors. If every treatment is a unique cancer protein there is no common factor. The treatment is the confounding factor.
To put it another way. A safety trial has to prove that any protein administered is safe.
Edit: just realised you're probably talking about efficacy trials, whereas I'm more concerned with safety.